Dieter Hölzel1, Renate Eckel1, Ingo Bauerfeind2, Bernd Baier3, Thomas Beck4, Michael Braun5, Johannes Ettl6, Ulrich Hamann5, Marion Kiechle6, Sven Mahner7, Christian Schindlbeck8, Johann de Waal3, Nadia Harbeck9, Jutta Engel10. 1. Munich Cancer Registry (MCR) of the Munich Tumour Centre (TZM), Institute for Medical Information Processing, Biometry and Epidemiology (IBE), University Hospital of Munich, Ludwig-Maximilians-University (LMU), Tumorregister München, Klinikum Großhadern/IBE, 81377, Munich, Germany. 2. Head of the Breast Cancer Project Group of the Munich Tumour Centre (TZM) and of Department of Obstetrics and Gynaecology, Klinikum Landshut, Landshut, Germany. 3. Department of Obstetrics and Gynaecology, Klinikum Dachau, Dachau, Germany. 4. Department of Obstetrics and Gynaecology, Klinikum Rosenheim, Rosenheim, Germany. 5. Department of Gynaecology, Rotkreuzklinikum, Munich, Germany. 6. Department of Obstetrics and Gynaecology, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany. 7. Department of Obstetrics and Gynaecology, University Hospital of Munich, Ludwig-Maximilians-University (LMU), Munich, Germany. 8. Department of Obstetrics and Gynaecology, Klinikum Traunstein, Traunstein, Germany. 9. Breast Centre, Department of Obstetrics and Gynaecology, University Hospital of Munich, Ludwig-Maximilians-University (LMU), Munich, Germany. 10. Munich Cancer Registry (MCR) of the Munich Tumour Centre (TZM), Institute for Medical Information Processing, Biometry and Epidemiology (IBE), University Hospital of Munich, Ludwig-Maximilians-University (LMU), Tumorregister München, Klinikum Großhadern/IBE, 81377, Munich, Germany. engel@ibe.med.uni-muenchen.de.
Abstract
PURPOSE: Systemic therapies (ATHs) in early breast cancer have improved the survival of breast cancer (BC) patients in recent decades. The magnitude of the changes in overall, metastasis-free (MFS) and post-metastatic (PMS) survival and in the metastasis (MET) pattern will be described. PATIENT AND METHODS: We analysed 60,227 patients with a diagnosis of T-N-M0 BC between 1978 and 2013 and 11,983 patients with metastases (MET) in the Munich Cancer Registry. Patients will be divided into four time periods to identify relationships between BC and METs. Survival was estimated using Kaplan-Meier curves, and Cox proportional hazards models were used to explore the impact of the BC subtype and MET status on survival with the time periods as surrogate markers for ATH evolution. RESULTS: During the observation period, 5-year relative survival has improved from 80.3 to 93.6% with an adjusted hazard ratio of 0.54 (P < 0.0001). Successful implementation of ATH has changed the MET pattern. The percentage of liver and CNS METs has more than doubled, the rate of lung METs remains stable, and the rate of bone METs has been reduced by approximately 50%. MFS has been prolonged with a hazard ratio 0.75 (P < 0.0001), but PMS has declined (hazard ratio 1.36; P < 0.0001); however, effects of adjuvant and palliative treatments cannot be separated. These results do not contradict improvements in advanced BC and do not suggest alterations of MET tumour biology by ATH. CONCLUSIONS: Over the past three decades, ATHs have dramatically improved patient survival after BC diagnosis-most likely, by eradicating prevalent micro-METs; as a result, the MET pattern has changed. Eradicating only a portion of the first METs results in delaying the onset of subsequent MET, which leads to an apparently paradoxical effect: an extension of the MET-free interval and a reduction in PMS.
PURPOSE: Systemic therapies (ATHs) in early breast cancer have improved the survival of breast cancer (BC) patients in recent decades. The magnitude of the changes in overall, metastasis-free (MFS) and post-metastatic (PMS) survival and in the metastasis (MET) pattern will be described. PATIENT AND METHODS: We analysed 60,227 patients with a diagnosis of T-N-M0 BC between 1978 and 2013 and 11,983 patients with metastases (MET) in the Munich Cancer Registry. Patients will be divided into four time periods to identify relationships between BC and METs. Survival was estimated using Kaplan-Meier curves, and Cox proportional hazards models were used to explore the impact of the BC subtype and MET status on survival with the time periods as surrogate markers for ATH evolution. RESULTS: During the observation period, 5-year relative survival has improved from 80.3 to 93.6% with an adjusted hazard ratio of 0.54 (P < 0.0001). Successful implementation of ATH has changed the MET pattern. The percentage of liver and CNS METs has more than doubled, the rate of lung METs remains stable, and the rate of bone METs has been reduced by approximately 50%. MFS has been prolonged with a hazard ratio 0.75 (P < 0.0001), but PMS has declined (hazard ratio 1.36; P < 0.0001); however, effects of adjuvant and palliative treatments cannot be separated. These results do not contradict improvements in advanced BC and do not suggest alterations of MET tumour biology by ATH. CONCLUSIONS: Over the past three decades, ATHs have dramatically improved patient survival after BC diagnosis-most likely, by eradicating prevalent micro-METs; as a result, the MET pattern has changed. Eradicating only a portion of the first METs results in delaying the onset of subsequent MET, which leads to an apparently paradoxical effect: an extension of the MET-free interval and a reduction in PMS.
Entities:
Keywords:
Breast cancer; Metastasis; Metastasis organs; Survival; Time trend
Authors: Corina J G van den Hurk; Renate Eckel; Lonneke V van de Poll-Franse; Jan Willem W Coebergh; Johan W R Nortier; Dieter Hölzel; Wim P M Breed; Jutta Engel Journal: Breast Cancer Res Treat Date: 2011-02-11 Impact factor: 4.872
Authors: Shaheenah Dawood; Kristine Broglio; Ana M Gonzalez-Angulo; Aman U Buzdar; Gabriel N Hortobagyi; Sharon H Giordano Journal: J Clin Oncol Date: 2008-08-25 Impact factor: 44.544
Authors: C Davies; J Godwin; R Gray; M Clarke; D Cutter; S Darby; P McGale; H C Pan; C Taylor; Y C Wang; M Dowsett; J Ingle; R Peto Journal: Lancet Date: 2011-07-28 Impact factor: 79.321
Authors: R Peto; C Davies; J Godwin; R Gray; H C Pan; M Clarke; D Cutter; S Darby; P McGale; C Taylor; Y C Wang; J Bergh; A Di Leo; K Albain; S Swain; M Piccart; K Pritchard Journal: Lancet Date: 2011-12-05 Impact factor: 79.321
Authors: Lucy R Yates; Moritz Gerstung; Stian Knappskog; Christine Desmedt; Gunes Gundem; Peter Van Loo; Turid Aas; Ludmil B Alexandrov; Denis Larsimont; Helen Davies; Yilong Li; Young Seok Ju; Manasa Ramakrishna; Hans Kristian Haugland; Peer Kaare Lilleng; Serena Nik-Zainal; Stuart McLaren; Adam Butler; Sancha Martin; Dominic Glodzik; Andrew Menzies; Keiran Raine; Jonathan Hinton; David Jones; Laura J Mudie; Bing Jiang; Delphine Vincent; April Greene-Colozzi; Pierre-Yves Adnet; Aquila Fatima; Marion Maetens; Michail Ignatiadis; Michael R Stratton; Christos Sotiriou; Andrea L Richardson; Per Eystein Lønning; David C Wedge; Peter J Campbell Journal: Nat Med Date: 2015-06-22 Impact factor: 53.440
Authors: Mitch Dowsett; Jack Cuzick; Jim Ingle; Alan Coates; John Forbes; Judith Bliss; Marc Buyse; Michael Baum; Aman Buzdar; Marco Colleoni; Charles Coombes; Claire Snowdon; Michael Gnant; Raimund Jakesz; Manfred Kaufmann; Francesco Boccardo; Jon Godwin; Christina Davies; Richard Peto Journal: J Clin Oncol Date: 2009-11-30 Impact factor: 44.544
Authors: Rachel F Dear; Kevin McGeechan; Marisa C Jenkins; Alexandra Barratt; Martin H N Tattersall; Nicholas Wilcken Journal: Cochrane Database Syst Rev Date: 2013-12-18
Authors: F Cardoso; E Senkus; A Costa; E Papadopoulos; M Aapro; F André; N Harbeck; B Aguilar Lopez; C H Barrios; J Bergh; L Biganzoli; C B Boers-Doets; M J Cardoso; L A Carey; J Cortés; G Curigliano; V Diéras; N S El Saghir; A Eniu; L Fallowfield; P A Francis; K Gelmon; S R D Johnston; B Kaufman; S Koppikar; I E Krop; M Mayer; G Nakigudde; B V Offersen; S Ohno; O Pagani; S Paluch-Shimon; F Penault-Llorca; A Prat; H S Rugo; G W Sledge; D Spence; C Thomssen; D A Vorobiof; B Xu; L Norton; E P Winer Journal: Ann Oncol Date: 2018-08-01 Impact factor: 32.976
Authors: Jana de Boniface; Marcus Schmidt; Jutta Engel; Marjolein L Smidt; Birgitte Vrou Offersen; Toralf Reimer Journal: Breast Care (Basel) Date: 2018-09-05 Impact factor: 2.860
Authors: Patriek Jurrius; Thomas Green; Hans Garmo; Matthew Young; Massimiliano Cariati; Cheryl Gillett; Anca Mera; Mark Harries; Anita Grigoriadis; Sarah Pinder; Lars Holmberg; Arnie Purushotham Journal: Breast Date: 2020-01-14 Impact factor: 4.380
Authors: S J Lord; K Bahlmann; D L O'Connell; B E Kiely; B Daniels; S A Pearson; J Beith; M K Bulsara; N Houssami Journal: EClinicalMedicine Date: 2022-01-29
Authors: Sarah J Lord; Belinda E Kiely; Sallie-Anne Pearson; Benjamin Daniels; Dianne L O'Connell; Jane Beith; Max K Bulsara; Nehmat Houssami Journal: BMJ Open Date: 2019-02-01 Impact factor: 2.692